Matica Biotechnology (Matica Bio) has opened a new 45,000 square foot facility dedicated to the production of viral vectors and cell-based products used in cell and gene therapies. Matica Bio is a contract development and manufacturing company (CDMO), which is a company within the pharmaceutical industry that provides drug development and manufacturing services. 

Matica Bio already has two collaborations at the new facility. The company is working with Sartorius to develop and optimize advanced viral vector manufacturing technologies for large-scale vector production, and is partnering with Texas A & M University’ Center for Innovation in Advanced Development and Manufacturing for projects to speed up biotech research and development and commercial manufacturing.

Matica Bio’s Jeong Song says the new building is key, “Our new facility is designed for rapid development, scale-up and production for clinical supply.”